

1 **A Phase 2 open-label study to determine the safety and efficacy of weekly dosing of ATL1102 in**  
2 **patients with non-ambulatory Duchenne muscular dystrophy**

3  
4 **Authors**

5 Woodcock IR<sup>123</sup>, Tachas G<sup>4</sup>, Desem N<sup>4</sup>, Houweling PJ<sup>2,3</sup>, Yiu EM<sup>123</sup>, Kean M<sup>5</sup>, Emmanuel J<sup>5</sup>, Kennedy  
6 R<sup>126</sup>, Carroll K<sup>127</sup>, de Valle K<sup>126</sup>, Adams J<sup>2</sup>, Lamandé SR<sup>2,3</sup>, Coles C<sup>2</sup>, Tiong C<sup>2</sup>, Villano D<sup>1</sup>, Button P<sup>8</sup>, Hogrel  
7 J-Y<sup>9</sup>, Catling-Seyffer S<sup>12</sup>, Delatycki MB<sup>1011</sup>, Ryan MM<sup>123</sup> for the ATL1102 in DMD clinical trial group.

8  
9 **Affiliations**

10 <sup>1</sup>Department of Neurology, The Royal Children's Hospital, Melbourne, Australia

11 <sup>2</sup>The Murdoch Children's Research Institute, Melbourne, Australia

12 <sup>3</sup>Department of Paediatrics, University of Melbourne, Australia

13 <sup>4</sup>Antisense Therapeutics Ltd, Melbourne, Australia

14 <sup>5</sup>Department of Medical Imaging, The Royal Children's Hospital, Melbourne, Australia

15 <sup>6</sup>Department of Physiotherapy, University of Melbourne, Australia

16 <sup>7</sup>Department of Physiotherapy, Monash University, Australia

17 <sup>8</sup>McCloud Consulting Group, Sydney, Australia

18 <sup>9</sup>Institut de Myologie, GH Pitié-Salpêtrière, Paris, France

19 <sup>10</sup>Victorian Clinical Genetics Service, Melbourne, Australia

20 <sup>11</sup>Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute,  
21 Melbourne, Australia

22

23

24

25

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 26 **Abstract**

27 **Background:** ATL1102 is a 2'MOE gapmer antisense oligonucleotide to the CD49d alpha subunit of  
28 VLA-4. ATL1102 inhibits expression of CD49d on lymphocytes, thereby reducing their survival,  
29 activation and migration to sites of inflammation. Children with Duchenne muscular dystrophy (DMD)  
30 have dystrophin deficient muscles. These are susceptible to contraction induced injury which triggers  
31 the immune system, exacerbating muscle damage. CD49d is a biomarker of disease severity in DMD,  
32 with increased numbers of high CD49d expressing T cells correlating with more severe and progressive  
33 weakness, despite corticosteroid treatment.

34 **Methods:** This Phase 2 open label study assessed the safety, efficacy and pharmacokinetic profile of  
35 ATL1102 administered as 25 mg weekly by subcutaneous injection for 24 weeks in 9 non-ambulatory  
36 boys with DMD aged 10–18 years. Participants receiving corticosteroid therapy were allowed into the  
37 study if on a stable dose for at least 3 months. The main objective was to assess safety and tolerability  
38 of ATL1102. Secondary objectives included the effect of ATL1102 on lymphocyte numbers in the blood,  
39 functional changes in upper limb function as assessed by Performance of Upper Limb test (PUL 2.0)  
40 and upper limb strength using MyoGrip and MyoPinch compared to baseline.

41 **Results:** ATL1102 was generally safe and well tolerated. No serious adverse events were reported.  
42 There were no participant withdrawals from the study. The most commonly reported adverse events  
43 were injection site erythema and skin discoloration. There was no statistically significant change in  
44 lymphocyte count from baseline to week eight (mean change  $-0.56 \times 10^9/L$  95%CI -1.52, 0.40), week  
45 twelve (mean change  $-0.53 \times 10^9/L$  95%CI -1.65, 0.58) or week twenty-four (mean change  $-0.28 \times 10^9/L$   
46 95%CI -1.10, 0.55) of dosing however, the CD3+CD49d+ T lymphocytes were statistically significantly  
47 higher at week 28 compared to week 24, four weeks past the last dose (mean change  $0.40 \times 10^9/L$  95%CI  
48 0.05, 0.74;  $p=0.030$ ). Functional muscle strength, as measured by the PUL2.0, EK2 and Myoset grip  
49 and pinch measures, and MRI fat fraction of the forearm muscles were stable throughout the trial  
50 period.

51 **Conclusion:** ATL1102, a novel antisense drug being developed for the treatment of inflammation that  
52 exacerbates muscle fibre damage in DMD, appears to be safe and well tolerated in non-ambulant boys  
53 with DMD. The apparent stabilisation observed on multiple muscle disease progression parameters  
54 assessed over the study duration support the continued development of ATL1102 for the treatment  
55 of DMD.

56

57

## 58 **Introduction**

59 Duchenne muscular dystrophy (DMD), a severe, progressive, X-linked genetic muscle disease is the  
60 most common muscle disorder in boys, affecting 1 in 5000 live male births worldwide.(1) Boys with  
61 DMD have onset of progressive muscle weakness in the first decade of life, with death due to  
62 cardiorespiratory failure expected in the late third or early fourth decades.(2) Currently the only  
63 disease modifying medical treatment is corticosteroid therapy, which delays loss of ambulation by a  
64 median 3 years, to 13 years of age(3-5) but carries a significant treatment burden of adverse effects.(5)  
65 DMD is associated with absence of dystrophin from muscle. This causes increased susceptibility to  
66 contraction-induced muscle damage, with activation of the innate immune macrophages in turn  
67 activating the adaptive immune system T lymphocytes, leading to upregulation of pro-inflammatory  
68 cytokines, including the extracellular structural protein osteopontin, resulting in chronic inflammation,  
69 fibrosis and reduced muscle strength.(6) CD49d, the alpha chain subunit of integrin very late antigen  
70 4 (VLA-4) is expressed widely on immune cells in this cascade and can bind osteopontin. (7) In patients  
71 with DMD, the number of CD49d high expressing T lymphocytes is inversely proportional to  
72 ambulation speed, with highest concentration seen in non-ambulant patients.(8) Patients with higher  
73 concentrations have more severe weakness and are more likely to lose ambulation before 10 yrs of  
74 age despite corticosteroid use, suggesting CD49d may be a biomarker of disease severity or activity.(9)  
75 In ex vivo studies a monoclonal antibody to VLA-4 prevented patient T-cell binding to muscle cells and  
76 transendothelial migration, highlighting a potential therapeutic avenue.(9)

77 ATL1102 is a second-generation immunomodulatory 2'MOE gapmer antisense oligonucleotide which  
78 specifically targets human CD49d RNA. After binding to the RNA of CD49d, intracellular RNase H  
79 attaches resulting in downregulation of CD49d RNA. ATL1102 has previously been trialled to treat  
80 Relapsing Remitting Multiple Sclerosis (RRMS), noting that CD49d high expressing T cells are the  
81 effector and central memory T cells in RRMS. In this phase 2 RRMS clinical trial, ATL1102 dosed 200mg

82 three times weekly in the first week and twice weekly to 8 weeks substantially reduced inflammatory  
83 brain lesions by 88.5% and circulating lymphocytes and T lymphocytes by 25%.(10)

84 Reported here, collaborators from the same institution ran two separate but complementary studies.  
85 The initial trial, a phase 2 clinical trial examining for the first time the safety and efficacy of a low dose  
86 ATL1102 treatment for 24 weeks in non-ambulant patients with DMD on concomitant corticosteroid  
87 treatment. The second, a pre-clinical study in the *mdx* mouse model for DMD, conducted using a  
88 mouse specific second generation CD49d ASO (ISIS 348574) to show that monotherapy treatment can  
89 reduce CD49d mRNA expression in muscle and decrease contraction induced muscle damage.

90

## 91 **Methods**

### 92 *Ethics statement*

93 The clinical trial received approval from the Royal Children’s Hospital Human Research Ethics  
94 Committee with assigned number HREC/17/RCHM/121. The trial was subsequently registered at the  
95 Australian New Zealand Clinical Trials Registry (ACTRN12618000970246). An independent Data Safety  
96 Monitoring Board (DSMB) was established to provide safety oversight for the trial. Pre-clinical *mdx*  
97 mouse analyses were approved by the Murdoch Children’s Research Institute (MCRI) animal care and  
98 ethics committee (ACEC; approval number A899).

99

### 100 *Pre-clinical studies in mice*

101 The *mdx* mouse model is commonly used to study DMD. We tested efficacy of the second generation  
102 2’MOE gapmer mouse specific CD49d ASO ISIS 348574 as ATL1102 is specific to human CD49d RNA  
103 and not homologous to mouse. Mdx mice do not have circulating lymphocytes with high CD49d but  
104 have high CD49d expressing lymphocytes in the lymph nodes at 9 weeks.(11) Symptomatic 9 week old

105 *mdx* mice were treated for 6 weeks to determine the effect of ISIS 348574 on *CD49d* mRNA expression  
106 and muscle function measures.

107 Male *mdx* (n = 48) and age matched C57Bl10/J wild-type (WT, n = 12) controls were purchased from  
108 JAX laboratories at 5 weeks of age and acclimatised to the MCRI facility for a total of 4 weeks. Animals  
109 were housed in a specific-pathogen-free environment at a constant ambient temperature of 22°C and  
110 50% humidity on a 12 h light-dark cycle, with *ad libitum* access to food and water. The *mdx* mice were  
111 randomly assigned to 4 treatment groups (saline, low (5mg/kg) and high (20mg/kg) dose ISIS 348574,  
112 and a control gapmer oligonucleotide with the same 20 nucleotides scrambled such that it is not  
113 complementary to *CD49d* or other RNA (20mg/kg)). Mice (n = 12 /group) received weekly  
114 subcutaneous injections of saline, ISIS348574 and control oligonucleotide for a total of 6 weeks. The  
115 high dose (20mg/kg/week) equates to 1.6mg/kg/w dose in human equivalent body surface area (BSA)  
116 and the low dose (5mg/kg/week) equates to 0.4mg/kg/week dose on BSA. After treatment mice were  
117 anaesthetised using inhaled isoflurane (0.6 ml per min) and muscle function was examined using the  
118 Arora Scientific 1300A whole mouse test system and 701C stimulator as previously published.(12)  
119 Mice were then euthanised by cervical dislocation and the spleen and skeletal muscle (quadriceps)  
120 were collected for further analysis.

#### 121 *Flow cytometry*

122 The *mdx* spleen was perforated to isolate the splenic sub-cellular content and incubated in red blood  
123 cell lysis buffer (Thermofisher) for ten minutes at 4°C. Splenocytes were centrifuged 1500 g for five  
124 minutes at 4°C. Cell pellets were washed in wash buffer (PBS:1% BSA (bovine albumin serum)). CD4+  
125 and CD8+ T cell populations were identified using anti-CD4-V450 (Biolegend, San Diego, CA , USA) and  
126 anti-CD8a-allophycocyanin – cyanine 7 (anti-CD8a-APC-Cy7) (Biolegend, San Diego, CA , USA). Stained  
127 cells were analysed using BD LSRFortessa™ X-20 Cell Analyzer to identify populations of CD4+ and  
128 CD8+ T cells.

129

### 130 *Clinical Trial Design*

131 This was a phase 2 open-label clinical trial assessing the safety of ATL1102 in non-ambulant boys with  
132 DMD concomitantly with standard of care corticosteroid therapy. Inclusion criteria for the clinical trial  
133 are included in the supplementary data Figure 1.

134 Participants received weekly subcutaneous injections of 25mg of ATL1102 for twenty-four weeks.  
135 Injections were administered into subcutaneous fat of the abdomen by a registered nurse or trained  
136 parent. Injection sites were rotated in quadrants around the umbilicus. Parents monitored injection  
137 sites for cutaneous reactions and participant discomfort for forty-eight hours post-administration.  
138 Adverse events were recorded in a diary which was returned to the study coordinators at each  
139 fortnightly visit.

140 Participants underwent fortnightly venepuncture for exploratory and safety blood tests. This included  
141 monitoring of haematology, biochemistry and inflammatory markers and at point of care urinalysis  
142 dipstick to monitor kidney function. Participants were seen monthly by the study team for physical  
143 examination and respiratory function assessments.

144 Participant safety was monitored routinely and at regularly scheduled meetings by the independent  
145 DSMB.

146

### 147 *Outcome Measurements*

148 The primary endpoint of the trial was safety of ATL1102 as assessed by the frequency and intensity of  
149 adverse events, including injection site reactions and any laboratory value derangement.

150 Secondary outcome measures included both laboratory and functional efficacy endpoints. Laboratory  
151 efficacy outcome measures included lymphocyte-modulation activity determined by cell surface flow  
152 cytometry measuring variation in the number and percentage of total lymphocytes as well as those

153 CD4 and CD8 T lymphocytes expressing high levels of CD49d (CD49dhi) to week twenty-four of  
154 treatment and to week twenty-eight, four weeks past the last treatment.

155 Changes in upper limb muscle strength and function were measured at baseline and again at weeks  
156 five, eight, twelve and twenty-four. Muscle function was assessed by a questionnaire-based outcome  
157 measure of disease burden (Egen Klassifikation Scale version 2 - EK2) and performance-based  
158 measures (the Performance of the Upper Limb scale version 2 (PUL 2.0), and the Moviplate 30 second  
159 finger tapping score of the MyoSet tool). The MyoSet tool also measured distal upper limb strength as  
160 determined by the MyoPinch (key pinch strength) and MyoGrip (hand grip strength) scores.(13-15)  
161 Other outcome measures assessed were respiratory function (forced vital capacity (FVC) and forced  
162 expiratory volume in one second (FEV1)), and quality of life assessed using the neuromuscular module  
163 of the Pediatric Quality of Life Instrument (PedsQL NMD™).

164

#### 165 *Muscle Magnetic Resonance Imaging (MRI)*

166 Participants underwent MRI of the dominant forearm at baseline, week twelve and week twenty-four.  
167 Unilateral upper-limb MRI was performed at 1.5T (Siemens Aera; Siemens, Erlangen, Germany) using  
168 a flexible surface matrix coil (4-Channel Flex Coil) wrapped around the forearm. Participants lay in the  
169 scanner in the head-first supine position, with the arm to be imaged lying in a comfortable position  
170 on the scanner bed alongside the torso. Two point-Dixon images were acquired (3D gradient-echo  
171 TE1/TE2/TR = 2.39/4.44/6.99ms, flip angle 10°, nine 6mm axial slices, slice gap 0mm, FOV 18x18cm,  
172 matrix 320x320, pixel size 0.56x0.56mm, NEX = 4). Fat fraction maps were obtained using on scanner  
173 tools.

174 Change over time in muscle composition (atrophy, oedema and fatty infiltration) was measured on  
175 the muscles of the central, proximal, and distal forearm using Short Tau Inversion Recovery (STIR) and  
176 3-point Dixon sequences on MRI. Changes in muscle composition were scored using the semi-

177 quantitative visual scoring Mercuri method and by quantitative fat fraction analysis.(16-18) Due to  
178 fatty infiltration, identification of individual muscles was challenging, such that a compartment  
179 composite score of volar, dorsal and ECRLB Br (extensor carpi radialis longus/brevis and  
180 brachioradialis) compartments was used as per a previous published study.(19) The lean muscle mass  
181 was calculated using previously published methods: Cross-sectional muscle compartment area x ( (100  
182 – total muscle compartment fat percent) / 100).(19)

183

#### 184 *Statistical analysis*

185 Based upon data from a previous study of ATL1102 in RRMS patients analyzing blood 3 days after the  
186 last dose in week 8, the laboratory efficacy end point of lymphocyte modulation potential was  
187 established as a reduction in total lymphocyte count of  $0.47 \times 10^9/L$  (25% reduction).(10) For the sample  
188 size calculation, the level of significance was set to 0.05 with a 2-sided paired t-test, mean difference  
189 of  $0.47 (x10^9/L)$  from baseline to end of treatment, and standard deviation of  $0.428 (x10^9/L)$ . A sample  
190 size of 9 participants was calculated as required to achieve a power of 80%. Data were analysed using  
191 SAS® Version 9.4. primary and secondary efficacy measures were analysed using the paired t-test and  
192 the non-parametric Wilcoxon sign-rank test. The study was not powered to see a change on the  
193 secondary efficacy endpoints from baseline to end of treatment.

194

## 195 **Results**

### 196 *Proof of concept preclinical study using mdx mice*

197 *Ex vivo* analyses of monocytes collected from *mdx* mice (n = 3), showed that the ASO to mouse CD49d,  
198 ISIS 348574 can reduce the expression of CD49d mRNA (Fig. 1A). We then examined the *in vivo*  
199 response to ISIS 348574 in *mdx* mice treated for 6 weeks which showed that *CD49d* mRNA expression  
200 was reduced in skeletal muscle by approximately 40% when treated with either a low (5mg/kg/week)

201 or high (20mg/kg/week) dose of ISIS 348574, compared to saline controls (Fig. 1B, One-way ANOVA  
202 with Tukey correction,  $p = * <0.05$ ,  $** <0.01$ ).

203 This study also found that *mdx* mice treated with the 20mg/kg/week dose of ISIS 348574 showed a  
204 reduction in the percentage of splenic CD4+ (30%,  $p < 0.05$ ) and CD8+ (21%,  $p < 0.05$ ) T lymphocytes,  
205 compared to saline treated mice (Fig. 1C and D). Furthermore *in situ* muscle function analyses show  
206 that the high dose (20mg/kg/week) treated *mdx* mice were protected from the effects of eccentric  
207 muscle damage, producing 72% of the original muscle force (SEM  $\pm 6$ ,  $P < 0.01$ ). This was in contrast to  
208 *mdx* mice treated with either saline, scrambled control or low dose (5mg/kg) ISIS 348574, which  
209 generated approximately 50% of the original force following eccentric muscle contractions. (Fig 1. E  
210 and F, One-way ANOVA with Fishers LSD test,  $p = * <0.05$ ,  $** <0.01$ ,  $*** <0.001$ ).

211

## 212 *Clinical Trial Results*

213 Eleven adolescent males with DMD were screened for participation. All had been non-ambulant for at  
214 least six months prior to screening. Two screened participants were excluded (one participant had  
215 started cardioprotective medication within three months of the initial visit and the other participant  
216 exceeded the pre-determined weight limit for inclusion).

217 Nine participants were enrolled into the open-label study. All had a confirmed pathogenic variant in  
218 DMD, with a clinical phenotype consistent with DMD as assessed by their treating/referring clinician  
219 and the study investigator. Participant demographics are summarized in Table 1.

220

## 221 *Safety*

222 There were no serious adverse events (SAEs) or suspected or unexpected serious adverse reactions  
223 (SUSARs). A total of 136 adverse events were recorded (table 2), with all participants reporting at least  
224 one adverse event. Sixty-three percent of the reported adverse events were injection site related, with

225 all but one participant experiencing transient erythema within twenty-four hours of the  
226 administration of ATL1102. Six (67%) participants had mild post-inflammatory hyperpigmentation of  
227 the skin of their abdomen which was persistent; four had resolved and two were ongoing but  
228 improving at the post completion follow-up study visit. The hyperpigmentation was noticed in the first  
229 participant after receiving eleven weekly doses of ATL1102. The DSMB was made aware and the  
230 participant informed consent form updated. In the five subsequent participants who had a similar  
231 reaction it was seen after four to eleven doses. The hyperpigmentation was not regarded as a clinical  
232 safety concern by the DSMB. Pain, discomfort or atrophy of the subcutaneous tissues were not  
233 reported, and there were no signs of systemic involvement. No participants withdrew from the study.  
234 There were no other significant adverse events felt to be related to ATL1102 or its administration.

235

### 236 *Efficacy*

237 *Lymphocyte Count:* There was no statistically significant decrease in lymphocyte count from baseline  
238 to week eight, week twelve or week twenty-four of dosing (Table 3). There was no statistically  
239 significant decrease in CD49d+CD3+CD8<sup>+</sup> or CD49d+CD3+CD4<sup>+</sup> T lymphocytes seen between baseline,  
240 weeks 8, 12 or 24 (table 3). This 9 participant trial did not achieve the pre-specified laboratory activity  
241 outcome measure of a significant  $-0.47 \times 10^9/L$  (25% reduction) in total lymphocyte count.

242

243 There was, though, a consistent trend toward declines in the mean number of lymphocytes, and  
244 CD49d+ T lymphocytes measured 3 days post-dose at week 8, 12 and 24. The mean number of  
245 CD3+CD49d+ T lymphocytes (i.e. CD3+CD4<sup>+</sup> and CD3+CD8<sup>+</sup> expressing CD49d) measured at week 28  
246 was statistically significantly higher compared to end of dosing at week 24 (mean change  $0.40 \times 10^9/L$   
247 95%CI 0.05, 0.74; paired T-Test,  $p=0.030$ ) (Table 3). Repeated measures analysis of CD3-CD49d+ NK  
248 lymphocytes in a *post hoc* analysis comparing baseline to a linear combination of values measured

249 three days post-dose at weeks 8, 12 and 24 was significantly lower compared to baseline ( $p=0.018$ ),  
250 with comparable NK lymphocyte numbers at week 28.

251

### 252 *Functional Outcome Measures*

253 There were no statistically significant changes in any upper limb functional outcome measures at week  
254 24 compared to baseline (table 4). The PUL2.0 score remained stable with no significant change  
255 between baseline and week twenty-four with a mean increase in PUL2.0 score (less disease impact)  
256 of 0.9 (95%CI -1.33, 3.11). EK2 scores were stable throughout the trial period. ATL1102 treatment  
257 showed no significant effect on lung function throughout the 24 week trial period (table 4). The  
258 components of the Myoset all reflected stable grip and pinch strength over the course of the trial.

### 259 *MRI*

260 In this trial, there was some variation in the quality of proximal and distal slices due to variable  
261 positioning of the participant's forearm in consecutive scans. The quality of the central slices through  
262 the muscle body in the forearms muscles was not compromised and so this measurement was chosen  
263 for detailed comparison between baseline and week 24 scans for each participant. No significant  
264 change was apparent between baseline and week twenty-four for the mean Mercuri semi-  
265 quantitative score of fatty infiltration (0.1 point change), atrophy (0 point change) and muscle oedema  
266 (0.3 point change) measuring the central slice around the elbow (table 6). There was a trend towards  
267 minor improvement in the percentage fat fraction in all muscle groups measuring the central slice,  
268 although statistical significance was not achieved. There was no significant pattern of change in cross-  
269 sectional muscle area of any muscle group (table 5).

270

### 271 *Correlation of parameters assessed in the Phase 2 study*

272 Correlation analyses were performed across assessment measures PUL2.0, Myoset and MRI.

273 Positive correlations were observed in the Phase 2 study between the different measures of muscle  
274 function of Moviplate scores and the PUL 2.0 scores of the distal domain ( $r = 0.664$ ) which support the  
275 consistency of the observed changes across the measures assessed in the study over the 24 week  
276 ATL1102 treatment period (See supplementary data Figure 2).

277 Positive correlations were also observed in the Phase 2 study between the MRI results of the lean  
278 muscle area (non-fat) and MyoGrip results ( $r = 0.604$ ), suggesting a consistency of results across the  
279 different parameters of muscle structure and muscle strength (See supplementary data Figure 3).

280

## 281 **Discussion**

### 282 *Safety*

283 This open-label phase 2 clinical trial met its primary safety end point. All but one participant  
284 experienced post-injection site erythema, swelling or discomfort suggesting that the investigation  
285 product is a mild irritant, as has been observed with other MOE antisense drugs, and is commonly  
286 reported with subcutaneously injected drugs. Future clinical trials of ATL1102 could consider including  
287 using ice as a pre-injection site treatment to minimise these reactions. Six participants experienced an  
288 unexpected post-inflammatory skin hyperpigmentation which resolved or faded at the completion of  
289 the study. Interestingly this reaction has not been previously reported in other clinical trials of  
290 ATL1102 and was not viewed as a safety concern.(10)

291 The dose chosen for this 24 week trial (25mg/week) was considered as a presumed safe dose in this  
292 patient population. In a previous phase 2 trial in individuals with RRMS a loading dose of 200mg every  
293 other day for one week was administered then 400mg/week (twice weekly 200mg) for seven  
294 weeks.(10) This DMD trial was the first clinical trial to investigate the safety of ATL1102 over a six-  
295 month period.

296

297 *Lymphocyte Modulation*

298 Given the previously observed action of ATL1102 of reducing lymphocytes in the RRMS study, the trial  
299 sample size was calculated to see a 25% reduction in total lymphocyte count when the drug is at  
300 equilibrium from week 8. This activity endpoint was not met in this trial. There was however a  
301 consistent trend toward declines in the mean number of lymphocytes at week 8, 12 and 24 each  
302 measured 3 days past dosing, and statistically significant reductions in the mean number of CD49d+  
303 NK lymphocytes at week 8, 12 and 24 weeks of treatment, using repeated measures analysis. The  
304 mean number of CD49d+ T lymphocytes (i.e CD3+CD4+ and CD3+CD8+ that are CD49d+) was  
305 statistically significantly higher at week 28 compared to week 24, indicating a rebound elevation of  
306 CD49d+ T lymphocytes four weeks post the last treatment dose. These results collectively suggest that  
307 ATL1102 suppresses CD49d expressing lymphocytes at a dose of 25mg per week. It is anticipated that  
308 higher doses will increase the level of lymphocyte reduction whilst maintaining a favourable safety  
309 profile in part due to sparing of the majority of T lymphocytes and NK lymphocytes. Future studies will  
310 look at dose escalation as supported by this study, and modelling with ATL1102.

311

312 *PUL2.0 and EK2 upper limb function*

313 PUL2.0 measures shoulder, elbow, and wrist finger dimensions of disease burden and is a reliable  
314 measure of disease severity and progression in DMD. The mean change from baseline to week twenty-  
315 four in PUL2.0 was an increase in function by 0.9 (95% CI -1.33 to 3.11). Although the Minimal Clinical  
316 Important Difference (MCID) for the PUL2.0 has not been established, previously published data from  
317 a historical cohort suggested that over a twelve month period a mean decrease in PUL2.0 score of  
318 2.17 can occur, albeit in a cohort not directly comparable to the participants in the phase 2 study due  
319 to older age and larger proportion not on corticosteroids.(20) An external historical cohort with same  
320 inclusion criteria as in the ATL1102 phase 2 trial, showed a decrease in PUL2.0 score of 2.0 (standard  
321 deviation 3.02) from baseline over a six month period.(21) In the ATL1102 phase 2 study four of the

322 nine patients achieved an increase in their PUL2.0 score of +2, and another three patients were  
323 stabilized in the PUL2.0 score (Table 5). This is an encouraging trend that warrants further  
324 investigation.

325 There was no change in the EK2 over the course of the trial period. This composite outcome measure  
326 encompasses multiple aspects of disease burden and as such is a useful clinical monitoring tool (higher  
327 score equals greater disease burden) but is not likely to be as responsive as the PUL2.0 measure to  
328 small changes in upper limb function. As such, a stabilisation over the six month trial periods is  
329 encouraging and needs to be confirmed in future studies.

330

### 331 *Myoset Tests: MoviPlate, MyoGrip, and MyoPinch*

332 The MyoSet functional outcome measures consist of the MoviPlate muscle function assessment of  
333 repetitive flexion extension of the wrist and fingers, and MyoGrip and MyoPinch assessment of muscle  
334 grip and pinch strength. (13, 14) These measures have been validated for use in clinical trials of DMD;  
335 MyoGrip and MyoPinch in particular have been shown to be sensitive to change in non-ambulant boys  
336 and to correlate well with lean muscle mass on MRI.(15) There was no change in any of these measures  
337 over the trial period. Previous natural history studies have shown significant deterioration over six  
338 months (Grip -0.5kg [95%CI -1.01; 0.002] and Pinch -0.38kg [95%CI -0.53; -0.22]). (18, (15) Matching  
339 the MyoGrip and MyoPinch protocol with that of a previously published natural history cohort allowed  
340 for comparison of change in grip and pinch strength over a six month period, yielding a statistically  
341 significant improvement on grip (p=0.03) and pinch (p=0.003) strength.(19) The lack of decline in these  
342 measures with ATL1102 during the trial period is once again encouraging and warrants further  
343 investigation.

344

### 345 *MRI of Upper Limb*

346 Magnetic Resonance Imaging of muscle is increasingly used as a biomarker for disease stage and  
347 progression. The most widely used scoring method is the Mercuri Score, which requires a skilful  
348 investigator to visually score the chosen muscles based upon a standardised set of criteria  
349 encompassing degree of atrophy, oedematous changes and fatty infiltration of the muscle, to create  
350 an aggregate score. The more recent development of automated fat fraction analysis reduces the  
351 inter-user variability and provides a more quantitative measure of assessment. Matching the MRI  
352 protocol with that of a previously published natural history cohort allowed for direct comparison of  
353 change in fat fraction over a six month period.(19) From this published natural history data, disease is  
354 expected to progress with a mean increase of central forearm muscle fat fraction percentage of 3.9%  
355 (95%CI 1.9,5.7) over six months. The apparent trend towards a decrease in mean forearm muscle fat  
356 fraction of 0.52% (95% CI -5.62, 4.58; Median 1.4%) seen after six months of treatment with ATL1102  
357 may suggest that ATL1102 could be modifying the rate of fatty infiltration into these muscles.  
358 Comparison of the mean change in fat fraction analysis of the central slice of the total muscle  
359 compartment between this study population and those of the natural history cohort published does  
360 not yield a significant difference ( $p=0.079$ ). For future MRI studies it would be important to set a  
361 clearer protocol with imaging tags placed over surface landmarks to ensure uniformity of subsequent  
362 scans.

363

## 364 **Conclusion**

365 The proof of concept pre-clinical data supports a potential protective effect of an antisense  
366 oligonucleotide to CD49d RNA in the mdx mouse model of DMD. This phase 2 open-label clinical trial  
367 has shown that ATL1102 has a good safety profile and is well tolerated with minor injection site  
368 reactions the only treatment-related adverse events reported. The positive observations in functional  
369 efficacy outcomes suggesting stabilization, and results compared with historical natural history data,  
370 particularly the PUL2.0, MyoGrip, MyoPinch and MRI fat fraction analysis, justifies the ongoing drug

371 development program of ATL1102 in non-ambulant boys with DMD and provides a rationale to  
372 proceed with larger placebo-controlled studies of this novel therapeutic agent.

373

374

375 **Acknowledgements:**

376 The authors wish to acknowledge the contribution of Isabelle Ledoux and Simone Birnbaum of the  
377 Insitute of Myology, Paris, France who provided support with the quality control and analysis of the  
378 MyoSet functional outcome measures; Valeria Ricotti of the Dubowitz Neuromuscular Centre,  
379 London UK, who provided support on the comparative analysis of the MRI observations; and  
380 Annabell Leske and Vicky Beal and the team at Avance Clinical, Adelaide, Australia.

381 **Tables and Figures**

382 *Table 1: Summary of Participant Demographics*

Characteristic	Category	Statistic	ATL1102 N = 9
Sex	Male	n (%)	9 (100)
Age (years)		Mean (SD)	14.9 (2.1)
		Median (range)	14.0 (12 - 18)
Weight (kg)		Mean (SD)	52.7 (9.8)
Height (cm)		Mean (SD)	141.1 (10.0)
BMI		Mean (SD)	27.1 (7.4)
Time since non-ambulant (years)		Median (range)	2.2 (0.6 – 9.2)
Corticosteroid Medication	Yes	n (%)	8 (88.9)
	<i>Prednisolone</i>		3 (33.3)
	<i>Deflazacort</i>		5 (55.6)

383

384 Table 2: Treatment Emergent Adverse Events reported in at least two participants

<b>SYSTEM ORGAN CLASS</b> Preferred Term	All N=9 Participants (%) [No. of Events]
Participants reporting any AEs	9 (100.0%) [136]
<b>GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</b>	
Injection site erythema	8 (88.9%) [59]
Injection site pain	5 (55.6%) [7]
Injection site swelling	3 (33.3%) [6]
Injection site bruising	4 (44.4%) [4]
Pyrexia	2 (22.2%) [4]
<b>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</b>	
Skin discolouration	6 (66.7%) [7]
<b>GASTROINTESTINAL DISORDERS</b>	
Vomiting	2 (22.2%) [4]
Constipation	2 (22.2%) [2]
<b>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</b>	
Cough	2 (22.2%) [2]
Nasal congestion	2 (22.2%) [2]
Oropharyngeal pain	2 (22.2%) [2]
<b>INFECTIONS AND INFESTATIONS</b>	
Lower respiratory tract infection	2 (22.2%) [2]
Nasopharyngitis	2 (22.2%) [2]
<b>NERVOUS SYSTEM DISORDERS</b>	
Migraine	2 (22.2%) [2]

385

386

387

388 *Table 3: Summary of lymphocytes mean change from baseline to weeks 24 and 28*

White blood cell type (X10 <sup>9</sup> cells per litre)	Mean Baseline count (x10 <sup>9</sup> cells per litre)	Mean Change from baseline		Median percentage change from baseline (%)		Paired T-Test (p value) of mean change between week 28 and 24
		Week 24	Week 28	Week 24	Week 28	
Lymphocytes	3.68	-0.28	+0.19	-4.22	+11.81	0.051
CD3+ T cells	2.93	-0.18	+0.25	0.86	+17.11	0.056
CD3+ CD49d+ T cells	2.44	-0.28	+0.11	-9.78	+9.93	0.03*
CD3+ CD4+ T cells	1.57	-0.15	+0.11	-1.12	+16.50	0.063
CD3+ CD4+ CD49d+ T cells	1.20	-0.19	+0.01	-16.7	+1.73	0.073
CD3+ CD8+ T cells	1.22	-0.02	+0.14	-2.62	+17.99	0.068
CD3+ CD8+ CD49d+T cells	1.17	-0.05	+0.11	-5.79	+13.37	0.064

389

390 The Lymphocyte mean number of cells at week 24 (at the end of dosing) is trending significantly lower vs week  
391 28 (p= 0.051 paired T test)

392

393 \*The mean number of CD3+CD49d+T lymphocytes (CD4+CD49d+ and CD8+CD49d+ T lymphocytes) at week 24  
394 is statistically significantly lower vs week 28 (p=0.030 paired T test)

395

396

397

398 *Table 4: Change in Functional Outcome Measures from baseline to week 24.*

399

Change from Baseline to Week 24									
Patient No.	PUL 2.0	MyoGrip (dom) (Kg)	MyoGrip (dom) (% Pred)	MyoPinch (dom) (Kg)	MyoPinch (dom) (% Pred)	MoviPlate Score (dom)	% Predicted FVC	% Predicted PEF	EK2*
01-001	+2	-0.63	-4.49	0.03	-0.62	-14.0	-3.20	6.30	+1
01-002	+2	0.22	0.49	-0.02	-0.29	13.0	-14.8	-17.3	+1
01-003	0	0.68	1.02	-0.40	-6.59	-3.0	-9.10	8.70	+2
01-004	+2	1.09	1.01	0.37	2.99	7.0	0.80	7.20	+2
01-006	-3	-0.27	-0.60	0.07	0.94	8.0	-6.50	6.90	-6
01-008	+7	1.00	1.11	0.30	2.77	3.0	-7.70	-18.2	-1
01-009	0	-0.33	-3.75	-0.22	-4.97	7.0	-9.10	-4.30	+2
01-010	0	0.05	0.11	0.06	0.72	-15.0	-0.40	9.20	-1
01-011	-2	0.11	-1.31	-0.18	-3.63	11.0	-1.10	2.00	+2
Mean Change (95% CI):	0.9 (-1.33, 3.11)	0.2 (-0.25, 0.67)	-0.7 (-2.33, 0.90)	0.0 (-0.18, 0.19)	-1.0 (-3.56, 1.63)	1.9 (-6.08, 9.85)	-5.68 (-9.60, -1.76)	0.06 (-8.33, 8.44)	0.2 (-1.80, 2.25)
*Higher score = greater disability									
*Reduction in Fat Fraction (%) = improvement									

400

401

402 Table 5: Change in the MRI Central reading fat fraction, cross sectional area and lean muscle mass from baseline to week  
403 24.

Mean Change (95% CI) from Screening/Baseline to Week 24		
MRI Parameter	N	MRI Central Reading Mean (95%CI)
<b>Fat Fraction (%)</b>		
Volar Muscle	9	-0.57 (-7.81, 6.68)
Dorsal Muscles	9	-0.88 (-3.41, 1.65)
ECRLB-Br	9	-0.12 (-6.42, 6.17)
Average Fat Fraction	9	-0.52 (-5.62, 4.58)
<b>Cross Sectional Muscle Area (mm<sup>2</sup>)</b>		
Volar Muscle	9	22.78 (-31.2,76.73)
Dorsal Muscles	9	0.89 (-18.9,20.65)
ECRLB-Br	9	-1.33 (-8.94, 6.28)
Total Area	9	22.33 (-36.8,81.42)
Lean Muscle Mass (mm <sup>2</sup> )	9	13.9 (72.6, 100.4)

404 ECRLB-Br = extensor carpi radialis longus/brevis and brachioradialis.

405 Volar Muscles: flexor digitorum profundus and flexor pollicis longus (FDP), flexor digitorum superficialis and palmaris longus (FDS), flexor  
406 carpi ulnaris (FCU), flexor carpi radialis (FCR)

407 Dorsal Muscles: Extensor carpi ulnaris (ECU), extensor digiti minimi (EDM), extensor digitorum (ED), extensor pollicis longus (EPL), abductor  
408 pollicis longus (APL), extensor carpi radialis longus/brevis and brachioradialis (ECRLB-Br), but the ECRL-BR are not included in the Dorsal  
409 muscle measurement in the Central Reading

410 Change in the MRI Proximal reading average Fat Fraction (%) from baseline to week 24 was -2.14 [95%CI -7.60; 3.3] for the  
411 9 patients.


412

413 Table 6: Mercuri visual semi-quantitative score in whole forearm compartment from baseline to week 24.

Whole Forearm			
	Baseline	Wk 24	Change
Fatty Infiltration	5.2	5.3	0.1
Atrophy	1.6	1.6	0.0
Oedema	2.6	2.9	0.3

414

415 Figure 1:



416

417 Figure 1: Pre-clinical data using the *mdx* mouse model of DMD to test the effects of ISIS 348574 (mouse specific *Cd49d*  
418 oligonucleotide to ATL 1102) *in vivo*.

419 A) Monocytes were isolated from the spleens of *mdx* mice (n = 3) and exposed to a single dose of ISIS 348574 for 48hrs *in vitro* to show  
420 that we could achieve a reduction in *CD49d* mRNA using ISIS 348574 to mouse *CD49d* RNA.

421 B) Following 6 weeks of treatment *CD49d* mRNA expression was reduced in mice treated with either the low (5mg/kg/week) or high  
422 (20mg/kg/week) dose of ISIS 348574, compared to saline controls (One-way ANOVA with Tukey correction, p = \* <0.05, \*\* <0.01).

423 C and D) Proportion of CD4+ and CD8+ T cells from the spleens of *mdx* mice with and without ISIS 348574 drug treatment. Cells are  
424 expressed as a proportion of total live cells isolated from the spleen. One way ANOVA with Fishers LSD test, \* p < 0.05.

425 E and F) *In situ* muscle physiology analyses shows that *mdx* mice treated with either saline (red, ~45% force recovery), scrambled (grey,  
426 ~45% force recovery) or low dose (orange, ~ 50% force recovery) ISIS 348574 were susceptible to eccentric muscle contraction damage  
427 compared to wild-type (black) controls, whereas the mice treated with a high dose of ISIS 348574 were resistant to the effects of eccentric  
428 muscle damage and produced 72% of the original force following the eccentric muscle damaging protocol. This was still significantly less  
429 than the 95% force recovery seen in WT mice, however this improvement in force following a muscle damage protocol suggests that the  
430 use of a 20mg/kg/week dose of ISIS 348574 was able to protect the muscles of *mdx* mice. One-way ANOVA with Fishers LSD test,  $p = *$   
431  $<0.05$ ,  $** <0.01$ ,  $*** <0.001$ ,  $**** <0.0001$ ).

432

433 **Supplementary Data:**

434

435 *Table 7: Participant specific genetic variant within Dystrophin Gene*

Participant Number	Specific Genetic Variant within Dystrophin Gene
1001	Deletion of exons 48-50
1002	splice site mutation in intron 45
1003	deletion of exon 50
1004	duplication within exon 15 causing premature stop codon
1006	deletion of exon 50
1008	deletion of exons 8-27
1009	nonsense substitution mutation in exon 23 causing premature stop codon
1010	nonsense mutation in exon 52 causing a premature stop codon
1011	deletion of exons 8-25

436

437

438

## 439 *Supplementary Data:*

### 440 Figure S1: Inclusion and Exclusion criteria for the clinical trial

#### 441 Inclusion Criteria: Participants who:


- 442 1. Are adolescent males, aged 10 to 18 years inclusive, at the time of providing informed consent.
- 443 2. Have been diagnosed with Duchenne Muscular Dystrophy and have been non-ambulatory for at least 3 months.
- 444 Non-ambulatory for this study is defined as having consistently required a wheelchair to mobilise more than a
- 445 few metres for at least 3 months.
- 446 1. The diagnosis of DMD is to be confirmed by at least one of the following:
- 447 a. Dystrophin immunofluorescence and/or immunoblot showing near complete dystrophin protein
- 448 deficiency, and clinical picture consistent with typical DMD; or
- 449 b. Gene deletion test positive (missing one or more exons) of the dystrophin gene, where the reading
- 450 frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD; or
- 451 c. Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other
- 452 mutation resulting in a stop codon) that can be definitely associated with DMD, with a typical clinical
- 453 picture of DMD; or
- 454 d. Positive family history of DMD confirmed by one of the criteria listed above in a sibling or maternal
- 455 uncle, and clinical picture typical of DMD.
- 456 3. Have a body weight of more than 25 kg and less than or equal to 65 kg.
- 457 4. If currently receiving glucocorticoid therapy, have been on a stable dose of glucocorticoid therapy for at least 3
- 458 months prior to Day 1.
- 459 5. Are currently on stable doses of cardiac therapy (including angiotensin converting enzyme inhibitors, aldosterone
- 460 receptor antagonists and/or beta blockers) for at least 3 months prior to Day 1.
- 461 6. Have a parent/guardian who is capable of understanding the purposes and risks of the study and able to provide
- 462 written informed consent. If the participant is of sufficient maturity and has the ability to understand the nature
- 463 and consequence of the study, involvement in study consent discussions are required.
- 464 7. Are able, and have a parent/guardian who are, willing and able to comply with scheduled visits, study drug
- 465 administration plan, and study procedures.

#### 466 Exclusion Criteria: Participants who:

- 467 1. Have been diagnosed with Duchenne Muscular Dystrophy and are still ambulatory. Ambulatory for this study is
- 468 being able to complete at least 75 meters during the 6-minute walk test in the 4 weeks prior to Day 1.
- 469 2. Have the following abnormal haematology values during the Screening period or on Day 1, prior to first dose:
- 470 a. Lymphocytes  $<1.2 \times 10^9/L$
- 471 b. Neutrophils  $<1.8 \times 10^9/L$
- 472 c. Platelets  $<150 \times 10^9/L$
- 473 3. Have a history of clinically significant bleeding or coagulation abnormalities.
- 474 4. Have hepatic dysfunction indicated by an abnormal total bilirubin and gamma glutamyl transferase (GGT) results
- 475 at Screening.
- 476 5. Have renal impairment indicated by serum creatinine  $\geq 1.5$  mg/dL (132  $\mu\text{mol/l}$ ) at Screening.
- 477 6. Have uncontrolled clinical symptoms and signs of congestive heart failure consistent with Stage C or Stage D
- 478 criteria according to the American College of Cardiology/American Heart Association guidelines for cardiac
- 479 dysfunction within 3 months of Day 1.
- 480 7. Have an inability to complete the cardiac, pulmonary or strength range of motion and mobility assessments at
- 481 Screening.
- 482 8. Have taken nutritional, herbal, or antioxidant supplements that have a known demonstrated activity for
- 483 maintaining or improving skeletal muscle strength or functional mobility within 4 weeks of Day 1. NOTE: daily
- 484 multivitamin, Vitamin D or calcium supplements are permitted.
- 485 9. Are currently receiving antiplatelet or anticoagulant therapy, or have taken medication with an antiplatelet or
- 486 anticoagulant effect within 4 weeks prior Day 1 (e.g., aspirin).
- 487 10. Have received any investigational product in the 2 months prior to Screening (4 months if the previous drug was
- 488 a new chemical entity), whichever is longer.
- 489 11. Have severe behavioural disorder or inadequate cognitive development that would make them unable to comply
- 490 with the study assessments, which, in the opinion of the investigator, makes the participant unsuitable for
- 491 participation in the study.

492 *Figure S2: Correlation of the Moviplate scores and the PUL 2.0 distal dimension scores over the 24 Week ATL1102*  
493 *treatment period:*


494



495

496

497 *Figure S3: Correlation of the Grip Strength scores and the MRI data of the lean muscle area (non-fat) over the 24 week*  
498 *ATL1102 treatment period: The MRI is the determined lean muscle mass compartment across the mid (central) dominant*  
499 *forearm*



500

501

## 502 **References**

- 503 1. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifiro G. Global epidemiology of  
504 Duchenne muscular dystrophy: an updated systematic review and meta-analysis. *Orphanet J Rare*  
505 *Dis.* 2020;15(1):141.
- 506 2. Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmuller H. Life expectancy  
507 at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. *Eur J Epidemiol.*  
508 2020;35(7):643-53.
- 509 3. Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al.  
510 Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.  
511 *Neurology.* 2015;85(12):1048-55.
- 512 4. Bello L, Kesari A, Gordish-Dressman H, Cnaan A, Morgenroth LP, Punetha J, et al. Genetic  
513 modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne  
514 Natural History Study. *Ann Neurol.* 2015;77(4):684-96.
- 515 5. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and  
516 management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation,  
517 endocrine, and gastrointestinal and nutritional management. *Lancet Neurol.* 2018;17(3):251-67.
- 518 6. Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, et al. Immune-mediated  
519 pathology in Duchenne muscular dystrophy. *Sci Transl Med.* 2015;7(299):299rv4.
- 520 7. Zanotti S, Gibertini S, Di Blasi C, Cappelletti C, Bernasconi P, Mantegazza R, et al.  
521 Osteopontin is highly expressed in severely dystrophic muscle and seems to play a role in muscle  
522 regeneration and fibrosis. *Histopathology.* 2011;59(6):1215-28.
- 523 8. Pinto-Mariz F, Carvalho LR, de Mello W, Araujo Ade Q, Ribeiro MG, Cunha Mdo C, et al.  
524 Differential integrin expression by T lymphocytes: potential role in DMD muscle damage. *J*  
525 *Neuroimmunol.* 2010;223(1-2):128-30.
- 526 9. Pinto-Mariz F, Rodrigues Carvalho L, Pruber De Queiroz Campos Araujo A, De Mello W,  
527 Goncalves Ribeiro M, Cunha Mdo C, et al. CD49d is a disease progression biomarker and a potential  
528 target for immunotherapy in Duchenne muscular dystrophy. *Skelet Muscle.* 2015;5:45.
- 529 10. Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G, Group ATLS. CD49d antisense drug  
530 ATL1102 reduces disease activity in patients with relapsing-remitting MS. *Neurology.*  
531 2014;83(20):1780-8.
- 532 11. Lagrota-Candido J, Canella I, Savino W, Quirico-Santos T. Expression of extracellular matrix  
533 ligands and receptors in the muscular tissue and draining lymph nodes of mdx dystrophic mice. *Clin*  
534 *Immunol.* 1999;93(2):143-51.
- 535 12. Hogarth MW, Houweling PJ, Thomas KC, Gordish-Dressman H, Bello L, Cooperative  
536 International Neuromuscular Research G, et al. Evidence for ACTN3 as a genetic modifier of  
537 Duchenne muscular dystrophy. *Nat Commun.* 2017;8:14143.
- 538 13. Seferian AM, Moraux A, Annoussamy M, Canal A, Decostre V, Diebate O, et al. Upper limb  
539 strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne  
540 Muscular Dystrophy: an observational multicenter trial. *Plos One.* 2015;10(2):e0113999.
- 541 14. Servais L, Deconinck N, Moraux A, Benali M, Canal A, Van Parys F, et al. Innovative methods  
542 to assess upper limb strength and function in non-ambulant Duchenne patients. *Neuromuscul*  
543 *Disord.* 2013;23(2):139-48.
- 544 15. Hogrel JY, Wary C, Moraux A, Azzabou N, Decostre V, Ollivier G, et al. Longitudinal functional  
545 and NMR assessment of upper limbs in Duchenne muscular dystrophy. *Neurology.*  
546 2016;86(11):1022-30.
- 547 16. Mercuri E, Pichiecchio A, Counsell S, Allsop J, Cini C, Jungbluth H, et al. A short protocol for  
548 muscle MRI in children with muscular dystrophies. *Eur J Paediatr Neurol.* 2002;6(6):305-7.
- 549 17. Mercuri E, Pichiecchio A, Allsop J, Messina S, Pane M, Muntoni F. Muscle MRI in inherited  
550 neuromuscular disorders: past, present, and future. *J Magn Reson Imaging.* 2007;25(2):433-40.
- 551 18. Fischer D, Kley RA, Strach K, Meyer C, Sommer T, Eger K, et al. Distinct muscle imaging  
552 patterns in myofibrillar myopathies. *Neurology.* 2008;71(10):758-65.

- 553 19. Ricotti V, Evans MR, Sinclair CD, Butler JW, Ridout DA, Hogrel JY, et al. Upper Limb  
554 Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and  
555 Function Define Endpoints for Clinical Trials. Plos One. 2016;11(9):e0162542.
- 556 20. Pane M, Coratti G, Brogna C, Mazzone ES, Mayhew A, Fanelli L, et al. Upper limb function in  
557 Duchenne muscular dystrophy: 24 month longitudinal data. Plos One. 2018;13(6):e0199223.
- 558 21. Tachas G, Desem N, Button P, Pane E, and Mercuri E, World Muscle Society 2020, P.284  
559 ATL1102 treatment improves PUL2.0 in non-ambulant boys with Duchenne muscular dystrophy  
560 compared to a natural history control. Neuromuscular Disorders Volume 30, Supplement 1, S129-  
561 S130 October 1 , 2020, <http://dx.doi.org/10.1016/j.nmd.2020.08.28>